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2HRP Human Research Roadmap:
Risk and Gap
• Risk of Adverse Health Outcomes 
and Decrements in Performance due 
to Inflight Medical Conditions.
–Med02 “Pharmacy” Gap:  We do not 
have the capability to provide a safe 
and effective medication formulary for 
exploration missions.
3Med02 Gap Mitigation
Research Plan
• The new ExMC Med02 Gap Mitigation 
Research Plan was completed in July, 
2016.
• The goal of this research plan is to 
provide a research strategy aimed at 
mitigating the Med02 “Pharmacy” Gap 
by:
– delivering a recommendation for a 
chemically stable, safe, and effective 
medication formulary that will support the 
operational needs of exploration space 
missions.                   
4Research Strategy
• Content:
– evidence-based formulary and models
– innovative analytical tools and methodologies
– novel treatments and preventive measures 
• External Review: 
– Planned review by a panel of experts from 
the pharmaceutical industry, regulatory, and 
academic scientific communities            
(March 20, 2017) 
5Research Aim:  
Target 7 Critical Questions
1. What medications do we think we will need to provide for a 
specific Design Reference Mission (DRM)?
2. Which of the medications selected will be effective throughout the 
journey, (and which will not)?  
3. Of the medications that are not certain to be effective for the full 
mission duration, can we characterize what their likely effective 
shelf life will be? 
4. Can we provide the crew a way to determine if the medication is 
chemically stable, still active, or degraded in real-time?
5. As the formulary medications degrade, will they remain safe and 
effective, or will they become toxic?
6. Are there alternative methods for supplying formulary medications 
for an extended deep space mission?
7. Can we modify or replace existing pharmaceuticals to minimize the 
resource footprint or improve tolerance to the deep spaceflight 
environment?
6Research Portfolio Focus Areas:
The proposed approach to building a research 
portfolio aimed at mitigating the Med02 Gap, 
would be to target research in four major focus 
areas: 
• Formulary Selection
• Formulary Potency and Shelf life
• Formulary Safety and Toxicity
• Novel Technology Proof-of-Concept 
– Portable real-time chemical analysis 
– Innovative drug development / design
Formulary
Stability
Technology
Toxicity
7Formulary Selection:
Question 1:  What medications do we think we will need to 
provide for a specific Design Reference Mission (DRM)?
Projects:
• List of medications from targeted therapeutic classifications aimed at 
addressing anticipated medical events as suggested by:
– Data mining common medical events experienced during previous 
missions (EMR Tracking)
– Dose Tracker
– Medical Consumables Tracker
– Predictions obtained from the MONSTR
• Ongoing pharmaceutical product surveillance / technology watch 
– Surveillance of clinical / scientific literature
– Potomac Institute Pilot Project
Deliverables:
• Lists of promising formulary medication candidates for further 
evaluation
• Annual reports highlighting promising product development and 
technology 
8Formulary Design:  
The conceptual design of the exploration space formulary 
would consist of three components:
• Core Formulary:  Centralized, shared inventory consisting of 
those medications identified as high use or of significant or 
priority need (i.e. “Top 20”) 
• Personalized Formulary:  Small selection of medications used for 
chronic condition maintenance or based on therapeutic 
preferences, as selected by each individual crewmember (i.e. 
around 5 selections)
• Emergency Medicine Formulary:   Even smaller selection of 
medications consisting of critical emergency medications 
Emergency
Medicine
Personalized Formulary :
A small selection of 
medications based on 
crewmember preferences
Core Formulary
High use / need Medications
9Formulary Potency and Shelf life:
2. Which of the medications selected for 
an exploration space mission formulary 
will be effective throughout the journey, 
(and which will not)?  
3. Of the medications that are not certain 
to be stable for the full mission duration, 
can we characterize what their likely 
effective shelf life will be? 
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ISS Operational Medication Kit Shelf-life 
Duration Observational Study:
• Shelf-life duration data was compiled by the JSC 
Pharmacy from multiple operational ISS 
medication kits, over a 3 year period (9/2013 -
9/2016). 
• The ISS medication formulary observed 
consisted of 107 different medications.
• Shelf-life duration was determined by 
subtracting the time lost while preparing the 
operational medication kits for flight, from the 
manufacturer’s labeled expiration date.
– The Food and Drug Administration (FDA) requires 
that medications removed from the manufacturer’s 
original packaging be assigned an expiration date of 
only 1 year from the date of repackaging.  
What do we currently know?
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82%
15%
1% 2%
Data compiled by T. Bayuse et al, JSC Pharmacy, 2016 
Including the time lost when 
packing the kits for flight, only 16% 
of the ISS medical kit medications 
will have at least 2 years of shelf-
life remaining for in-flight use.
ISS Medical Kit Medication Shelf-life Duration Results
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Formulary Potency and Shelf life:
2. Which of the medications selected for an exploration space mission 
formulary will be effective throughout the journey, (and which will not)?  
3. Of the medications that are not certain to be stable for the full mission 
duration, can we characterize what their likely effective shelf life will be? 
Projects:
• Pharmaceutical stability studies 
– Ground-based
• Cory Stability Study:  College of Charleston, Charleston, SC (Completed)
• Wu Stability Study:  University of Houston, Houston, TX (Completed)
– Flight
• JSC Pharmacy “Dribble” Project (Maintain flight controls for opportunistic flight 
medication samples retrieved)
• Predictive stability modeling programs (Linear, non-linear, quantile 
regression) 
• Surveillance of clinical / scientific literature (i.e. SLEP study; eMC drug 
monographs)
Deliverables:
• Final project reports characterizing tested drug’s shelf life (Delivered), and 
portable technology validation  
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The Shelf Life Extension Program (SLEP):
• The federal SLEP Program was established 
in 1986, and administered by the U.S. 
Department of Defense (DoD) in cooperation 
with the FDA, to defer replacement costs of 
stockpiled medications and materials by 
extending their expiration dates.
– The FDA conducted all quality testing and 
medication evaluations for the SLEP Program, 
and discovered that the actual shelf life of 
products tested may be longer than their 
labeled expiration dates, dependent on their 
storage conditions.
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SLEP Study
Methods:
• 122 Medications stored in original packaging 
from 3005 different lots were tested using US 
pharmacopeia and FDA stability testing 
standards to determine shelf life extension 
data
Results:
• Overall, 2650 (88%) of the 3005 lots tested 
were extended past their original expiration 
dates with an average extension of 66 
months (Lyon et al, 2006).
– Only 7 medications tested in the SLEP program 
are included in the current ISS operational flight 
formulary.
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The Electronic Medicines Compendium (eMC)
• The electronic Medicines Compendium (eMC) 
contains up to date information about medicines 
licensed for use in the United Kingdom (UK). 
• All information on the eMC website comes directly 
from the 200 pharmaceutical companies that 
subscribe to the eMC; of which many have 
corporate headquarters in the United States.
• Pharmaceutical companies submit and update 
the Summaries of Product Characteristics (SPCs) 
provided by the eMC. 
– Within the SPC, the maximum shelf-life, or maximum 
amount of time the medication meets regulatory 
standards for potency based on drug stability testing, is 
provided.
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Formulary Potency and Shelf life:
4. Can we provide the crew a way to determine if the 
medication is chemically stable, still active, or degraded in 
real-time?
Projects:
• Portable Technology Assessment 
Proof-of-Concept
– Handheld Raman Spectroscopy: Real 
Time Analyzers 
– Liquid Chromatography (HPLC or 
UPLC) validation of portable 
technology: University of Houston, 
Houston, TX
Deliverables:
• Reports characterizing tested drug’s 
shelf life, and portable technology 
validation                                                                   
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Formulary Safety and Toxicity
5. As the formulary medications degrade, will they remain safe 
and effective, or will they become toxic?
Projects:
• In-vitro / In-vivo pharmaceutical degradation / toxicology studies 
• Modeling technology studies designed to generate dosing 
monographs adjusted for VAS medications with decreasing API 
content
Deliverables:
• A report summarizing results of in-vitro / in-vivo toxicity studies
• A final list of tested medications now VAS 
• Dosing monographs for VAS medications with reduced API 
VAS:  Verified As Safe     API:  Active Pharmaceutical Ingredient
This category to be 
investigated on an as-
needed basis
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Novel Technology and Innovation
6. Are there alternative methods for supplying formulary 
medications for an extended deep space mission?
7. Can we modify or replace existing pharmaceuticals to minimize 
the resource footprint or improve tolerance to the deep 
spaceflight environment?
Projects:
• Technology Watch (Element-directed Research) 
– Novel drug development techniques, dosage forms, and delivery systems to 
improve performance outcomes
• Research Pharmacist Surveillance 
• Potomac Institute Technology Watch Pilot Project (Completed)
Deliverables:
• Annual surveillance reports 
• Potomac Institute pilot project report (Delivered)
Future Needs:
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What Meds do we need?
Will they last long 
enough?
Can we characterize 
actual stability duration?
YES
No
Med 
Ops
MCT
Dose 
Tracker
List 1
List 2
List 3
List 4
Can we tell in real time 
when it is no longer 
good?
List 5
Lasts Long enough
Not long enough
RTA Project
Can we provide an 
alternative or another 
way?
Future Projects
Logic Diagram
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